相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population
Liv Tybjaerg Nordestgaard et al.
JAMA CARDIOLOGY (2022)
Macular Degeneration and CETP Inhibition
Alan R. Tall et al.
JAMA CARDIOLOGY (2022)
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Katerina Dangas et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Amand F. Schmidt et al.
NATURE COMMUNICATIONS (2021)
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Gregory G. Schwartz et al.
DIABETES CARE (2020)
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
Jean-Claude Tardif et al.
AMERICAN HEART JOURNAL (2020)
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
Venu Menon et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Impact of ADCY9 Genotype on Response to Anacetrapib
Jemma C. Hopewell et al.
CIRCULATION (2019)
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease A Nested Case-Control Study
Steven E. Nissen et al.
JAMA CARDIOLOGY (2018)
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination
R. Krishna et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial
Stephen J. Nicholls et al.
ATHEROSCLEROSIS (2017)
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance With Clinical Outcomes
Jean-Claude Tardif et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance With Clinical Outcomes
Jean-Claude Tardif et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial
Stephen J. Nicholls et al.
AMERICAN HEART JOURNAL (2015)
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Jean-Claude Tardif et al.
Circulation-Cardiovascular Genetics (2015)
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib
Stephen J. Nicholls et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
G. Kees Hovingh et al.
LANCET (2015)
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
John J. P. Kastelein et al.
LANCET (2015)
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Jean-Claude Tardif et al.
Circulation-Cardiovascular Genetics (2015)
HDL and glucose metabolism: current evidence and therapeutic potential
Andrew L. Siebel et al.
FRONTIERS IN PHARMACOLOGY (2015)
Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease
Antonio M. Gotto et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2014)
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
Thomas F. Luescher et al.
EUROPEAN HEART JOURNAL (2012)
Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors
Shenping Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Trine Holm Johannsen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
The emerging role of HDL in glucose metabolism
Brian G. Drew et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip J. Barter et al.
CIRCULATION (2011)
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol A Randomized Controlled Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
Zahi A. Fayad et al.
LANCET (2011)
Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion
Michelle A. Fryirs et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography The Ludwigshafen Risk and Cardiovascular Health Study
Andreas Ritsch et al.
CIRCULATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors
Menno Vergeer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Philip Barter
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community
Ramachandran S. Vasan et al.
CIRCULATION (2009)
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Stephen J. Nicholls et al.
CIRCULATION (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Michiel L. Bots et al.
LANCET (2007)
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
Lee A. Morehouse et al.
JOURNAL OF LIPID RESEARCH (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
Tomas Vaisar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The forgotten majority - Unfinished business in cardiovascular risk reduction
P Libby
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
ME Brousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis
PJ Barter et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
H Okamoto et al.
NATURE (2000)
Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
CW Rittershaus et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
